VA
JAZZ icon

Vident Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Vident Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.35M Sell
23,032
-517
-2% -$90.4K 0.04% 390
2025
Q4 		$4M Sell
23,549
-1,426
-6% -$219K 0.04% 392
2025
Q3 		$3.29M Sell
24,975
-8,649
-26% -$1.04M 0.03% 417
2025
Q2 		$3.57M Buy
33,624
+7,415
+28% +$805K 0.04% 349
2025
Q1 		$3.25M Sell
26,209
-3,053
-10% -$398K 0.05% 329
2024
Q4 		$3.6M Buy
29,262
+217
+0.7% +$25.6K 0.06% 280
2024
Q3 		$3.24M Buy
29,045
+26,917
+1,265% +$2.95M 0.08% 257
2024
Q2 		$227K Sell
2,128
-122,131
-98% -$13.4M 0.01% 1238
2024
Q1 		$15M Buy
124,259
+35,347
+40% +$4.33M 0.31% 101
2023
Q4 		$10.9M Buy
88,912
+86,702
+3,923% +$10.8M 0.27% 118
2023
Q3 		$286K Buy
+2,210
New +$294K 0.01% 933

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vident Advisory's JAZZ Position: Q1 2026 in Review

Vident Advisory reduced its Jazz Pharmaceuticals (JAZZ) stake by 2.2% in Q1 2026, selling an estimated $90.4K and leaving 23,032 shares worth $4.35M. The position accounts for 0.04% of the portfolio, ranked #390.

Vident Advisory first reported a position in JAZZ in Q3 2023 and has held it in 11 quarters since. The position peaked at $15M in Q1 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Vident Advisory held 23,032 shares of Jazz Pharmaceuticals worth $4.35M as of Q1 2026.
  • Vident Advisory sold 517 Jazz Pharmaceuticals shares in Q1 2026, an estimated $90.4K.
  • Jazz Pharmaceuticals made up 0.04% of Vident Advisory's portfolio in Q1 2026, its #390 holding.
  • Vident Advisory first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Vident Advisory's Jazz Pharmaceuticals position peaked at $15M in Q1 2024.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.